In the future, iPSC-derived BRCA1+/− iMSCs could have important applications in high-throughput drug screening and the testing of new drugs to prevent or to cure hereditary breast and/or ovarian cancers by specifically targeting the stromal compartment with germline BRCA1 mutations. This evidence concerns the gene BRCA1 and ovarian carcinoma.